Revcovi

Chemical Nameelapegademase-lvlr
Dosage FormInjection (intramuscular; 0.2 mg/kg, 0.4 mg/kg)
Drug ClassOligonucleotides
SystemBlood
CompanyLeadiant Biosciences, Inc.
Approval Year2018

Indication

  • To treat adenosine deaminase severe combined immunity deficiency.
Last updated on 6/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Revcovi (Elapegademase-lvlr) Prescribing Information 2018Leadiant Biosciences, Inc., Gaithersburg, MD